How to Choose a Formulation Partner for Your Supplement

Do You Actually Need a Separate Formulator?

Not every brand needs a separate formulator. Our recommendation: start by asking your shortlisted contract manufacturers whether their existing formulas and development teams can meet your brief. A suitable stock formula may meet your needs. A separate specialist is worth comparing when your chosen format, ingredients, or production-transfer needs exceed the manufacturer's scope.

Write a short brief before requesting quotes. Include the intended consumer, dosage form, serving size, ingredient constraints, desired claims, packaging, target unit cost, and first-run quantity. Mark which items are fixed and which the formulator can challenge. Ask for the evidence behind proposed ingredients, doses, and claims.

With separate partners, name who will manage the handoff. Ask the manufacturer to review the proposed formula before you approve development milestones. Confirm who pays for changes needed to run it on that facility's equipment.

Neither an independent consultant nor an in-house team wins by default. Use these questions to compare the actual proposal:

• 1.Why were these ingredient forms and sources selected? What evidence, cost, availability, and production constraints shaped the choice?
• 2.Is this a stock formula, a modified stock formula, or new development? What, if anything, will be exclusive to your brand?
• 3.What rights and files will you receive? Can another facility make the product, and what would that transfer require?

Not sure whether you need custom formulation at all? See our Private Label vs Custom Formulation comparison.

Types of Formulation Partners

Formulation partners fall into three broad categories. Each has different strengths, cost structures, and potential conflicts of interest.

Ask every candidate how they are paid: development fees, ingredient sales, commissions, referrals, or manufacturing revenue. A commercial relationship is not an automatic reason to reject a partner. It is a reason to ask for alternatives and the rationale behind their recommendation.

Scientific Credentials and Expertise to Verify

Ask who will do the work and how their experience fits your product. Include familiarity with dietary supplement CGMPs under Part 111. Ask who will assess ingredient and claim questions under DSHEA and whether any ingredient needs an NDI review. Do not assume a general scientific credential covers those responsibilities.

• Relevant degrees: Food science, pharmacology, chemistry, or biochemistry. Verify credentials rather than assuming them. Ask where they studied and whether they hold any professional certifications.
• Track record: Request comparable projects and references you can contact. If confidentiality prevents naming a brand, ask for a redacted technical example and another way to check their role.
• Category expertise: Ask how the team will handle the challenges of your product, such as botanical identity, probiotic viability, or a requested sport-certification program. Request an example in your specific dosage form.
• Ingredient form selection: Ask for the evidence supporting the selected ingredient form and dose. If the proposal claims better bioavailability, ask whether the study matches that form, dose, and intended use. Compare cost, serving size, taste, and manufacturing limits as well.
• Industry engagement: Ask for a recent example of evidence that changed their recommendation. Publications or conference talks can help you assess expertise, but do not replace relevant project evidence.

IP and Formula Ownership

Decide what control your business needs before agreeing to development terms. A stock formula license may suit a brand testing demand. A differentiated product may justify negotiating ownership of new work and stronger transfer rights.

Do not infer ownership from payment, a file label, or a release fee. Ask counsel to distinguish pre-existing know-how, newly developed work, ownership, licenses, and restrictions on use. Then check whether the agreement delivers the control you need.

Put the rights in writing: ask who owns each deliverable, what rights your company receives, when those rights take effect, and what survives termination. Discuss confidentiality before sharing sensitive details.

Agree on the production-transfer package:

• Formula quantities, ingredient specifications, approved sources, and agreed access to the Master Manufacturing Record (MMR)
• Process instructions, test methods, packaging specifications, development results, and any transfer support or fees

Treat legal rights, usable documentation, and production capability as separate checks. Ask a receiving manufacturer what it would need to reproduce the product. Files alone do not prove that transfer is permitted or that a new production process will work.

Questions to raise with your attorney:

• Which rights are assigned to my company, and which are licensed? What pre-existing technology is excluded?
• Does the agreement permit another facility to manufacture the product? Are there restrictions, approvals, or fees?
• What confidentiality protections fit the information we will share, and when do they start?
• Can the partner reuse the formula or sell it to another brand? What exclusivity, if any, are we buying?
• Who approves ingredient substitutions and formula changes? Who owns the revised work and pays for any retesting?

Have an attorney review any formulation agreement before signing. For more on contract structure, see our guide to quality agreements.

Stability Testing and Method Validation

Ask how the partner will support your proposed shelf life. Stability testing evaluates the product over time. A prototype, a passing release test, and a completed shelf-life study answer different questions.

Do not treat three months or 12 to 24 months as a universal supplement testing schedule. FDA's dietary supplement CGMP final rule did not require an expiration date. It stated that any date used, including a best-if-used-by date, should have supporting data. See the June 25, 2007 final rule, page 34856. Ask for a product-specific protocol, acceptance criteria, test methods, sampling dates, and final packaging.

Critical nuance for probiotics: The CRN/IPA voluntary guidelines (effective January 9, 2017, updated November 12, 2020), section II recommend real-time testing to support stated shelf life. Accelerated or other testing used to support product release should be scientifically justified and documented. Those are different decisions. Ask how the proposed study represents your finished product, final packaging, and labeled storage conditions.

A short quote does not prove testing was skipped. It may cover only a written formula or first samples. Ask which results will exist at each milestone, what prior data the partner is relying on, and who will manage any continuing study.

Cost Expectations

Use published prices to understand scope, then request a quote for your brief. The table below uses one supplier, NaturPro Scientific, as a concrete example. It is not an industry average. Its page was checked September 18, 2026; prices and availability need confirmation with the supplier.

Source: NaturPro's published service table, checked September 18, 2026; page update date not stated. These are separate examples, not line items to add to the bundle. Benchtop samples are not a production-scale pilot run.

Ask each candidate to itemize formula development, sample rounds, raw materials, analytical work, stability studies, production-scale trials, packaging, and commercial inventory. For each item, record the deliverable, price, exclusions, owner, and acceptance criteria. Check what triggers a revised quote and whether development fees are credited toward your first order.

If your ingredient requires an NDI notification, ask for a separate scope and quote. Have the regulatory specialist identify what safety information already exists and what work is missing. Do not treat a development quote as covering ingredient-specific regulatory work unless it says so.

Compare milestones as carefully as totals. Ask for separate dates for the written formula, samples, manufacturing transfer, test results, and commercial production. Identify which tasks can overlap and which need an earlier result before they can start.

Questions to Ask Before Signing

Use these questions as a meeting checklist. Record the answer and the document that supports it, not just a verbal assurance.

• "What rights do we receive, and when?" Identify ownership, license terms, exclusions, and restrictions in the agreement.
• "What would another manufacturer need to make this product?" Agree on files, process information, permissions, support, and fees.
• "What supports the proposed shelf life?" Request the protocol, results available at release, remaining work, and the person responsible.
• "Who has worked on a comparable product?" Ask for relevant project evidence and a reference or redacted example.
• "Who approves a substitution?" Agree on change control, updated records, testing decisions, and cost responsibility.
• "What ingredient specifications and COAs will we receive?" Confirm they correspond to the materials used in the samples and proposed production formula.
• "What is excluded from the price?" Cover sample revisions, lab work, transfer, packaging, regulatory work, and commercial inventory.

Red Flags

Any of these should prompt deeper investigation before committing.

• IP ambiguity: The formulator will not put formula ownership in writing, or the contract is vague about who owns the final formula.
• No stability data: No one can identify the evidence behind the proposed shelf life or who will obtain it. The formulator may coordinate outside testing rather than perform it.
• Vague pricing: Pricing that changes after work begins, or quotes that do not itemize what is included. Ask for a written scope of work before starting.
• No supplement experience: A background exclusively in pharma, cosmetics, or food without dietary supplement projects. The regulatory framework is different enough to matter.
• Unrealistic timelines: A completion date without defined deliverables, testing milestones, or dependencies. Ask whether the date means formula-ready, sample-ready, or production-ready.
• No audit trail: The formulator cannot explain why they chose specific ingredients at specific doses. Every formulation decision should have a documented rationale.
• Cannot provide references: The partner offers neither contactable references nor a credible alternative that respects brand confidentiality. Ask how you can verify their work.
• Unclear exit costs: Transfer fees or support obligations are undefined until you want to leave. A fee alone does not establish who owns the formula.

Leave the selection process with a written product brief, itemized scope, rights agreement, testing plan, and named production-handoff owner. Those documents give you something concrete to compare before committing to development.

Browse our formulation and R&D directory to build a shortlist. Send candidates the same brief, then compare their answers against the checklist above. A directory profile is a starting point, not approval of your product or its development agreement.

Concepts Covered